Price T Rowe Associates Inc. MD lessened its holdings in shares of Catalent Inc (NYSE:CTLT) by 0.8% in the 2nd quarter, Holdings Channel.com reports. The firm owned 22,898,472 shares of the company’s stock after selling 194,246 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 0.16% of Catalent worth $1,241,326,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of CTLT. Highline Capital Management L.P. acquired a new position in shares of Catalent during the 2nd quarter worth about $111,494,000. Wells Fargo & Company MN raised its holdings in Catalent by 205.8% in the 2nd quarter. Wells Fargo & Company MN now owns 1,528,009 shares of the company’s stock valued at $82,833,000 after acquiring an additional 1,028,286 shares in the last quarter. BlackRock Inc. raised its holdings in Catalent by 7.9% in the 1st quarter. BlackRock Inc. now owns 13,918,974 shares of the company’s stock valued at $564,971,000 after acquiring an additional 1,023,315 shares in the last quarter. Viking Global Investors LP raised its holdings in Catalent by 50.5% in the 2nd quarter. Viking Global Investors LP now owns 1,595,579 shares of the company’s stock valued at $86,496,000 after acquiring an additional 535,066 shares in the last quarter. Finally, Lazard Asset Management LLC raised its holdings in Catalent by 149.5% in the 1st quarter. Lazard Asset Management LLC now owns 741,200 shares of the company’s stock valued at $30,085,000 after acquiring an additional 444,120 shares in the last quarter.
Several equities analysts have commented on the company. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a report on Monday, September 16th. UBS Group upped their price target on Catalent to $64.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Robert W. Baird upped their price target on Catalent from $50.00 to $60.00 and gave the company an “outperform” rating in a report on Wednesday, August 28th. Morgan Stanley upped their price target on Catalent from $50.00 to $61.00 and gave the company an “overweight” rating in a report on Wednesday, August 28th. Finally, Jefferies Financial Group raised Catalent from a “hold” rating to a “buy” rating and upped their price target for the company from $50.00 to $62.00 in a report on Friday, June 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Catalent has an average rating of “Buy” and an average target price of $57.00.
Shares of CTLT stock traded down $0.42 during trading hours on Tuesday, hitting $51.14. The company had a trading volume of 28,727 shares, compared to its average volume of 877,885. Catalent Inc has a 12 month low of $29.23 and a 12 month high of $58.38. The firm has a market capitalization of $7.53 billion, a price-to-earnings ratio of 31.57, a PEG ratio of 2.54 and a beta of 1.65. The firm’s fifty day moving average is $53.55 and its 200 day moving average is $48.84. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.70 and a current ratio of 2.08.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, August 27th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.03. Catalent had a return on equity of 15.89% and a net margin of 5.46%. The company had revenue of $725.70 million for the quarter, compared to analyst estimates of $719.20 million. During the same period in the prior year, the company posted $0.67 EPS. The company’s revenue was up 5.9% compared to the same quarter last year. On average, sell-side analysts expect that Catalent Inc will post 1.8 EPS for the current fiscal year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: How to Invest in Growth Stocks
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.